Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Modulation of atherosclerosis in mice by Toll-like receptor 2
Adam E. Mullick, Peter S. Tobias, Linda K. Curtiss
Adam E. Mullick, Peter S. Tobias, Linda K. Curtiss
View: Text | PDF
Research Article Cardiology

Modulation of atherosclerosis in mice by Toll-like receptor 2

  • Text
  • PDF
Abstract

Epidemiologic evidence has established a relationship between microbial infection and atherosclerosis. Mammalian TLRs provide clues on the mechanism of this inflammatory cascade. TLR2 has a large ligand repertoire that includes bacterial-derived exogenous and possibly host-derived endogenous ligands. In atherosclerosis-susceptible low-density lipoprotein receptor–deficient (Ldlr–/–) mice, complete deficiency of TLR2 led to a reduction in atherosclerosis. However, with BM transplantation, loss of TLR2 expression from BM-derived cells had no effect on disease progression. This suggested that an unknown endogenous TLR2 agonist influenced lesion progression by activating TLR2 in cells that were not of BM cell origin. Moreover, with intraperitoneal administration of a synthetic TLR2/TLR1 agonist, Pam3CSK4, disease burden was dramatically increased in Ldlr–/– mice. A complete deficiency of TLR2 in Ldlr–/– mice, as well as a deficiency of TLR2 only in BM-derived cells in Ldlr–/– mice, led to striking protection against Pam3CSK4-mediated atherosclerosis, suggesting a role for BM-derived cell expression of TLR2 in transducing the effects of an exogenous TLR2 agonist. These studies support the concept that chronic or recurrent microbial infections may contribute to atherosclerotic disease. Additionally, these data suggest the presence of host-derived endogenous TLR2 agonists.

Authors

Adam E. Mullick, Peter S. Tobias, Linda K. Curtiss

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Measurement of aortic atherosclerosis in Pam3-exposed TLR2 chimeric mice...
Measurement of aortic atherosclerosis in Pam3-exposed TLR2 chimeric mice. (A) Aortic atherosclerosis expressed as a percentage of total area after 12 weeks of an HFD and weekly i.p. injections of Pam3 in female Ldlr–/– mice that underwent BM reconstitution from Tlr+/+ or Tlr2–/– donor mice. (B–E) Representative aortae from Ldlr–/– recipient mice of the following groups: Tlr2+/+ BM donor, vehicle injection (B); Tlr2+/+ BM donor, 50 μg Pam3 per week (C); Tlr2–/– BM donor, vehicle injection (D); and Tlr2–/– BM donor, 50 μg Pam3 per week (E). Pam3 administration increased lesion severity in animals expressing TLR2 in their BM-derived cells resulting in profuse abdominal aortic atherosclerosis. Slight increases in lesion severity were observed in Tlr2–/– recipient animals receiving Pam3. Scale bar: 0.5 cm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts